Table 1 Baseline demographics and clinical characteristics of the study cohort.
Characteristic | Monotherapy group (n = 88) | Combination group (n = 361) | P-value |
|---|---|---|---|
Age, years (mean, SD) | 52.15 (13.35) | 50.02 (10.52) | 0.140 |
Female (n, %) | 65 (73.86%) | 294 (81.44%) | 0.077 |
Male (n, %) | 23 (26.14%) | 67 (18.56%) | 0.077 |
Disease duration, months (mean, range) | 95.22 (4.13–599.83) | 73.48 (3.10–450.80) | 0.134 |
LEF dose/day | |||
< 20 mg/day (n, %) | 39 (44.32%) | 200 (55.40%) | 0.074 |
≥ 20 mg/day (n, %) | 49 (55.68%) | 161 (44.60%) | 0.074 |
Therapeutic regimen | |||
LEF (n) | 88 | 0 | |
LEF + MTX (n) | 0 | 125 | |
LEF + HCQ (n) | 0 | 88 | |
LEF + MTX + HCQ (n) | 0 | 148 | |
